Levothyroxine vs Natural Desiccated Thyroid: Conversion, Dosing, and Clinical Protocols

What Is the Exact Conversion Ratio Between Levothyroxine and NDT?

The accepted clinical conversion is 100 mcg of levothyroxine to 60 mg of NDT (one grain). This ratio is derived from the fixed hormone content of desiccated porcine thyroid: each 60 mg grain contains roughly 38 mcg of T4 and 9 mcg of T3. Because T3 is approximately four times more biologically potent than T4 on a microgram-per-microgram basis, that 9 mcg of T3 contributes the hormonal equivalent of roughly 36 to 40 mcg of additional T4, putting the total T4-equivalent per grain near 75 to 78 mcg. The remaining potency difference is why the conversion sits at 100 mcg levothyroxine per grain rather than a simple 1:1 T4 match.

The American Thyroid Association's 2014 hypothyroidism management guidelines note that combination T4/T3 therapy may benefit a subset of patients, though the guidelines stop short of recommending NDT as a first-line agent for the general population. [1] A 2013 patient preference study published in the Journal of Clinical Endocrinology and Metabolism (N=70) found that 49% of participants preferred NDT over levothyroxine monotherapy after a blinded crossover, and patients on NDT lost an average of 4 lbs more over 16 weeks. [2]

Practical conversion table:

| Levothyroxine (mcg) | NDT (mg) | NDT (grains) | |---|---|---| | 25 | 15 | 1/4 | | 50 | 30 | 1/2 | | 75 | 45 | 3/4 | | 100 | 60 | 1 | | 125 | 75 | 1.25 | | 150 | 90 | 1.5 | | 200 | 120 | 2 |

When switching directions (NDT to levothyroxine), use the same ratio but confirm with a TSH and free T4 at 6 weeks. Do not assume a 1:1 swap is safe without lab verification.

How Is Levothyroxine Dosed by Body Weight?

For adults with no residual thyroid function (post-thyroidectomy or ablation), the standard full-replacement dose is 1.6 mcg per kg of body weight per day. [3] A 70 kg adult would start at approximately 112 mcg daily. Older adults (age <65 is a different risk profile than those over 70) and patients with cardiac disease typically start at 25 to 50 mcg with uptitration by 25 mcg every 4 to 6 weeks.

For patients with subclinical hypothyroidism or partial gland function, starting doses run lower, typically 25 to 75 mcg, because endogenous production fills part of the deficit. The 2019 European Thyroid Association guidelines recommend using ideal body weight rather than actual body weight in obese patients to avoid supra-therapeutic dosing, since adipose tissue does not significantly metabolize levothyroxine. [4]

Several variables shift the target dose upward or downward:

• Malabsorption disorders (celiac disease, short-gut syndrome) increase dose requirements by 20 to 50% in some patients. [5]
• Medications including calcium carbonate, ferrous sulfate, proton-pump inhibitors, and cholestyramine reduce levothyroxine absorption by up to 40% when taken simultaneously. [6]
• Liquid gel-cap formulations (Tirosint) may improve absorption in patients with gastric achlorhydria or on PPIs. [7]

Weight-based dosing is a starting point only. TSH measured 6 weeks after any dose change determines the next step.

What Are the T3 Dosing Protocols for Cytomel and Compounded Liothyronine?

Liothyronine (T3) is available as brand-name Cytomel in 5, 25, and 50 mcg tablets, or as compounded slow-release capsules from 503A/503B pharmacies. The short half-life of T3 (approximately 1 day compared to levothyroxine's 7-day half-life) means that immediate-release T3 produces a peak serum concentration within 2 to 4 hours, then falls. This pharmacokinetic profile is the core reason many clinicians who add T3 prefer twice-daily dosing or a compounded sustained-release formulation. [8]

Standard Cytomel add-on protocol (T4/T3 combination):

1. Reduce the current levothyroxine dose by 25 to 50 mcg.
2. Add liothyronine 5 mcg twice daily (morning and early afternoon, not at bedtime).
3. Check TSH, free T4, and free T3 at 6 weeks.
4. Titrate liothyronine in 2.5 to 5 mcg increments. Most patients stabilize at 5 to 15 mcg total daily T3.

Compounded slow-release T3 protocol: Doses of 7.5 to 20 mcg once daily (occasionally twice daily) are compounded into hydroxypropyl methylcellulose capsules. A 2013 randomized crossover trial published in Thyroid (N=46) found that slow-release T3 produced steadier serum T3 levels than immediate-release Cytomel while maintaining equivalent TSH suppression. [9] Slow-release compounded T3 is not FDA-approved but is legally dispensed under a valid prescription via 503A compounding pharmacies.

The FDA label for Cytomel (liothyronine sodium) specifies that the drug is indicated for hypothyroidism, myxedema coma, and thyroid suppression testing. [10] Off-label combination use requires shared decision-making and documented informed consent at most institutions.

Target free T3 on combination therapy: upper half of the laboratory's reference range (typically 3.0, 4.2 pg/mL on a 2.3, 4.2 pg/mL reference). A suppressed TSH <0.1 mIU/L on combination therapy signals over-replacement and warrants dose reduction.

How Should Levothyroxine Be Adjusted During Pregnancy?

Levothyroxine requirements increase by 25 to 50% during the first trimester, driven by rising hCG stimulation of the thyroid, increased thyroxine-binding globulin production, and expanded maternal blood volume. [11] The Endocrine Society's 2012 clinical practice guidelines on thyroid and pregnancy recommend that women with known hypothyroidism immediately increase their levothyroxine dose by two extra tablets per week (approximately a 29% increase) upon confirmed pregnancy, before waiting for TSH results. [12]

TSH targets during pregnancy differ by trimester:

| Trimester | TSH Target (mIU/L) | |---|---| | First (weeks 1, 12) | <2.5 | | Second (weeks 13, 26) | <3.0 | | Third (weeks 27, 40) | <3.0 |

These targets reflect the revised 2017 American Thyroid Association guidelines on thyroid disease in pregnancy, which lowered the first-trimester upper limit from the older 2.5 mIU/L threshold cited in prior decades. [13] Free T4 should remain in the upper normal range for gestational age.

NDT in pregnancy. There is no published randomized controlled trial on NDT use in pregnancy. The fixed T3 content causes transient maternal T3 peaks that cross the placenta to a limited degree; the clinical significance in euthyroid fetuses is unclear. Most maternal-fetal medicine specialists transition pregnant patients from NDT to levothyroxine monotherapy for easier titration and more predictable pharmacokinetics. Labs should be checked every 4 weeks through gestational week 20, then at minimum once between weeks 26 and 32. [13]

Post-partum, levothyroxine dose returns to the pre-conception dose immediately after delivery. Check TSH at 6 weeks post-partum to confirm.

What Lab Tests Are Required to Monitor Both Therapies?

Monitoring strategies differ between levothyroxine monotherapy and combination T4/T3 or NDT regimens because the assays capture different hormones.

Levothyroxine monotherapy: TSH alone is sufficient for stable, non-pregnant adults, per ATA guidelines. A normal TSH (0.5, 4.5 mIU/L on most platforms) confirms adequate replacement. [1] Free T4 adds value when TSH is discordant with symptoms, when pituitary disease is suspected, or during dose changes.

NDT or T4/T3 combination therapy: TSH remains the primary endpoint, but free T3 must also be measured. The exogenous T3 in NDT or Cytomel can suppress TSH to the low-normal range even when the patient is not over-replaced; in that setting, a suppressed-but-detectable TSH (0.1, 0.5 mIU/L) with free T3 in the upper reference range and absent symptoms of hyperthyroidism is generally acceptable. [14]

Draw blood in the morning, before taking the day's thyroid medication, and at least 4 hours after the last liothyronine dose to avoid measuring the post-dose T3 peak. This timing protocol applies to both Cytomel and NDT. [9]

A 2019 meta-analysis in Frontiers in Endocrinology pooled 11 studies (N=1,216) on combination T4/T3 therapy and found no significant difference in TSH, free T4, or quality-of-life scores at 6 months versus levothyroxine alone, though a subset analysis of patients with persistent symptoms on monotherapy showed modest improvement in cognitive function scores with combination therapy. [15]

Who Is a Candidate for NDT Instead of Levothyroxine?

NDT is not appropriate for every patient with hypothyroidism. It is a reasonable second-line option for patients who:

1. Report persistent fatigue, cognitive slowing, or weight resistance despite TSH in range on levothyroxine.
2. Prefer a naturally-derived product.
3. Have confirmed low-normal free T3 levels despite adequate TSH suppression (a pattern sometimes called "poor T4-to-T3 converter," linked to the DIO2 gene polymorphism rs225014). [16]

NDT is less suitable for patients with:

• Active cardiac arrhythmia or untreated coronary artery disease (the T3 bolus from NDT raises heart rate transiently).
• Pregnancy (see above).
• Adrenal insufficiency that has not been treated first, since T3 increases cortisol clearance and can precipitate an adrenal crisis.

The 2019 American Association of Clinical Endocrinologists and American Thyroid Association guidelines on hypothyroidism management state that evidence supporting the routine use of NDT over levothyroxine monotherapy remains insufficient, but acknowledge that some patients may report subjective benefit. [17] This is not a blanket prohibition. It is a call for individualized clinical judgment backed by consistent monitoring.

HealthRX Clinical Decision Framework: Choosing Between Levothyroxine and NDT

| Patient Scenario | Preferred Starting Therapy | Notes | |---|---|---| | New diagnosis, no cardiac history, age <60 | Levothyroxine | Easier to titrate; generic widely available | | Post-thyroidectomy, stable | Levothyroxine 1.6 mcg/kg/day | Full replacement; titrate to TSH 0.5, 2.0 | | Persistent symptoms on LT4, low free T3 | Trial of NDT or LT4 + T3 | Recheck at 8 weeks; document symptom scoring | | Pregnant or planning pregnancy | Levothyroxine monotherapy only | Increase dose 29% at confirmation of pregnancy | | Age >70, cardiac history | Levothyroxine, start 25 to 50 mcg | Avoid NDT due to T3 peak effect on heart rate | | DIO2 polymorphism confirmed | NDT or LT4 + low-dose T3 (5 mcg BID) | Genotyping not yet standard of care |

How Is the Switch from Levothyroxine to NDT Actually Done Clinically?

Most practitioners use a slow crossover rather than an abrupt switch. The T4 component of NDT absorbs similarly to levothyroxine, but the T3 component creates an early peak that can feel overstimulating if the starting NDT dose is too high.

Step-by-step conversion from levothyroxine 100 mcg to NDT 1 grain (60 mg):

1. Week 1, 2: Reduce levothyroxine to 75 mcg. Add NDT 1/4 grain (15 mg) in the morning. Take both on an empty stomach, 30 to 60 minutes before breakfast. [3]
2. Week 3, 4: If tolerating well (no palpitations, no excessive warmth), discontinue levothyroxine. Increase NDT to 1/2 grain (30 mg).
3. Week 5, 6: Increase to 3/4 grain (45 mg).
4. Week 7, 8: Increase to 1 grain (60 mg). Hold for 6 weeks.
5. Week 14: Check TSH, free T4, free T3. Adjust based on labs and symptoms.

Patients switching from NDT back to levothyroxine follow the reverse table, converting each 60 mg of NDT to 100 mcg of levothyroxine, then titrating to TSH target. Because levothyroxine has a 7-day half-life, TSH will not reflect the new dose for 4 to 6 weeks. [8]

A 2018 systematic review in The Cochrane Database found only 4 randomized trials of sufficient quality comparing NDT to levothyroxine, and none were adequately powered to determine superiority on patient-reported outcomes. [18] This evidence gap makes individualized monitoring protocols indispensable.

Absorption Timing and Drug Interactions: Practical Rules for Both Therapies

Thyroid hormones are absorbed in the small intestine; gastric pH, food, and competing ions all reduce absorption. These rules apply to both levothyroxine and NDT:

• Take the medication on an empty stomach, 30 to 60 minutes before the first meal, or at bedtime at least 3 hours after the last meal. A 2010 study in Archives of Internal Medicine (N=90) found that bedtime dosing raised free T4 by 17% and lowered TSH by 22% compared to morning dosing, suggesting improved absorption. [19]
• Separate calcium, iron, and magnesium supplements by at least 4 hours. [6]
• Separate antacids, sucralfate, and bile acid sequestrants by at least 4 hours. [6]
• Estrogen therapy (oral) increases thyroxine-binding globulin, raising dose requirements by 25 to 30% in hypothyroid women. Transdermal estrogen has minimal effect. [20]

Coffee taken within 60 minutes of levothyroxine reduces absorption by up to 36%, per a 2008 controlled study in Thyroid (N=8). [21] Tirosint liquid-gel capsule formulations are less affected by coffee and gastric pH because the hormone is pre-dissolved. [7]

Special Populations: Subclinical Hypothyroidism, Thyroid Cancer, and the Elderly

Subclinical hypothyroidism (TSH 4.5, 10 mIU/L, normal free T4): The TRUST trial (N=737, mean age 74) found no improvement in symptoms or quality of life with levothyroxine treatment versus placebo in older adults. [22] Current ATA guidance recommends treatment in patients under 65 with TSH consistently above 10 mIU/L, or in those with symptoms, positive anti-TPO antibodies, or cardiovascular risk factors. [1]

Thyroid cancer suppression therapy: Post-thyroidectomy patients with high-risk differentiated thyroid cancer require TSH suppression to <0.1 mIU/L; intermediate-risk patients target 0.1, 0.5 mIU/L. NDT is not appropriate for suppression therapy because the fixed T3/T4 ratio makes low-TSH titration imprecise. [23]

Elderly patients: Free T4-based dosing (rather than weight-based) is preferred for adults over 80. The risk of atrial fibrillation rises with over-replacement; a 2017 study in JAMA Internal Medicine found a 22% increased risk of atrial fibrillation in patients maintained at TSH <0.1 mIU/L compared to TSH 0.5, 1.5 mIU/L. [24]